share_log
Breakings ·  May 28 19:02
Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment